Form 4: Cytokinetics CEO Robert Blum Reports Stock Transactions Following Performance Stock Unit Vesting

Cytokinetics CEO Robert Blum acquired and disposed of shares following the vesting of Performance Stock Units, resulting in a net change in his holdings.

Summary

• Cytokinetics CEO Robert Blum reported transactions involving the company's common stock on December 3, 2024.
• These transactions include the acquisition of 11,529 shares upon vesting of Performance Stock Units (PSUs).
• A further 5,843 shares were disposed of to cover tax obligations related to the vesting of the PSUs at a price of $51.51 per share.
• Additionally, 11,530 shares of PSUs were acquired, which are subject to time-based vesting and will vest in full on December 3, 2025.
• After these transactions, Mr. Blum directly owns 414,894 shares of common stock.
• He also indirectly owns 2,083 shares through The Bridget Blum 2003 Irrevocable Trust and 2,083 shares through The Brittany Blum 2003 Irrevocable Trust.

Sentiment

Score: 7

Explanation: The document reflects routine transactions related to executive compensation. There is no indication of positive or negative sentiment, it is a standard filing.

Future Outlook

The document indicates that 11,530 shares of PSUs will vest on December 3, 2025.

Industry Context

This is a routine filing related to executive compensation and stock ownership, which is common in publicly traded companies. It does not indicate any unusual activity or trends within the biotechnology industry.

Comparison to Industry Standards

• Stock-based compensation, including PSUs, is a common practice in the biotechnology industry to incentivize and retain key executives.
• The vesting schedules and tax withholding practices described in the document are standard for such compensation plans.
• Similar filings are regularly made by executives at comparable companies such as Amgen, Gilead Sciences, and Biogen.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect routine executive compensation.
• The vesting of PSUs aligns executive interests with company performance.

Next Steps

• The 11,530 PSUs will vest on December 3, 2025.

Key Dates

Keywords

Cytokinetics, Robert Blum, Performance Stock Units, PSUs, stock transaction, insider trading, vesting, common stock